PDF
File
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Vård & Omsorg |
Copenhagen, Denmark, 28 May 2025 - Brain+ A/S (Nasdaq First North: BRAINP)
Brain+ A/S ("Brain+" or "the Company") has appointed Antony Hall, Managing Director of Park Homes UK, a leading care home group, as Strategic Advisor. The appointment follows the recent agreement between Brain+ and Park Homes UK to deploy Ayla to support high-quality dementia care in the group. Antony Hall is previous Director of HC-One, the largest care provider in the UK, and he has been Lead Inspector for the Care Quality Commission (CQC), which is a respected authority in UK overseeing care quality, dementia services, and care provision. Mr. Hall has a deep commitment to care quality implementation and broad insight into operational dementia care challenges, and he will provide pivotal support to Brain+ as commercial traction is building for the Ayla solution to deploy CST based high quality dementia care at scale. It has been agreed that Antony Hall invests his advisory fee into the Company.
Background
Brain+ accelerates the UK rollout of its flagship product, Ayla - your CST Assistant, a digital Cognitive Stimulation Therapy (CST) platform designed to deliver consistent, evidence-based dementia care at scale. Building on the clinically documented effects of CST, Ayla provides the basis for training of care staff and implementation of a new methodology for how to better treat and communicate with people affected by dementia.
Strategic importance of the appointment
The appointment of Antony Hall comes at a pivotal point in time, and it reflects Brain+' strategic focus on real-world implementation of CST in alignment with national dementia priorities and regulatory requirements. Mr. Hall's deep operational insight and system-level credibility within both the UK care home market and the CQC framework will support the Company's transition from early commercial traction to broader market integration across care homes and health care systems.
Antony Hall commented on his advisory role for Brain+: "I've spent my career striving to improve the quality of care for older people, and I've seen first-hand how overstretched the system has become. Ayla offers a compelling solution to one of the sector's biggest challenges: how to deliver meaningful, person-centred dementia therapy consistently and affordably. I'm excited to work with the Brain+ team to help scale this solution across the UK and beyond."
Driving market confidence
This appointment builds on Brain+' growing commercial and institutional momentum in the UK, including participation in the NHS Dementia Innovators Programme and recent sales agreements signed with two care home groups, Southcare Homes and Park Homes, for the deployment of Ayla to support high-quality dementia care based on the clinically documented effects of CST. It also follows publication of the CQC's national dementia report, which highlights critical gaps in staff training and in access to post-diagnostic support-needs Ayla is specifically designed to address.
By bringing in a seasoned leader with a proven track record in regulation, operations, and innovation, Brain+ further strengthens its market position and strategic execution capability.
Antony Hall will take on his advisory role with immediate effect, and to further demonstrate commitment to the Brain+ vision and the value offerings of Ayla he has opted to have his advisory fee paid in new shares in the Company.
Devika Wood, CEO of Brain+ said: "We are absolutely thrilled to welcome Antony Hall to the Brain+ team, as he brings unparalleled experience in dementia care delivery and regulatory oversight. His appointment signals strong endorsement of our strategy and strengthens our ability to execute with integrity, credibility, and impact. As we build the world's first scalable dementia care platform, Antony's guidance will be invaluable."
---
About Brain+
Brain+ A/S is a digital health company listed on Nasdaq First North Growth Market Denmark, building the world's first scalable dementia care platform. Its flagship product, Ayla - your CST Assistant, is a software-based tool designed to support the consistent delivery of Cognitive Stimulation Therapy (CST)-a clinically proven non-pharmacological, NICE-recommended intervention for people with mild to moderate dementia.
Contact Information
Devika Wood, CEO: + 44 7429 280366, devika@brain-plus.com
Hanne Vissing Leth, CFO: +45 53 88 99 02, hanne@brain-plus.com
Brain+ vision: Building the world's first scalable dementia care platform to help people affected by dementia, live better lives.